Deal Details

Keensight Capital Invests in CatSci 

---

Summary

About

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital’s team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €10 million to €400 million. Drawing on its expertise in the Healthcare and Technology sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision. Keensight Capital's success has earned it a Gold Award from the Private Equity Exchange & Awards each year for the last five consecutive years, and in particular, the Best European Growth Private Equity Fund.

CatSci Ltd provides end-to-end, perfect-for-purpose process research and development services to emerging, mid-sized, and large pharma companies, including four of the top five global pharmaceutical companies. CatSci has six operational laboratories across two UK sites fitted with the latest high-end equipment. CatSci is committed to developing economically and environmentally sustainable drug manufacturing processes that enable its global pharmaceutical customers to create affordable small molecule therapeutics to address critical public health challenges, including antimicrobial resistance, cancer, and mental health. CatSci is headquartered in the United Kingdom and formed in December 2010 from a spin-out of AstraZeneca’s Catalyst Screening Facility by five founders, including current co-owners Dr. Ross Burn and Dr. Simon Tyler, now CEO and COO, respectively.

---

CONTACT US TO LEARN MORE